Advanced Glycation End-Products and Arterial Stiffness in Hypertension

American Journal of Hypertension

Volumn 20, Issue 3, 2007, Pages 242-247

  McNulty, Marie ^a   Mahmud, Azra ^a,b   Feely, John ^a,b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

advanced glycation end products; aging; Arterial stiffness; augmentation index; hypertension; pulse wave velocity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CHOLESTEROL;

ADULT; AGING; AORTA; ARTERY DISEASE; ARTICLE; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEART RATE; HUMAN; HYPERTENSION; IMMUNOASSAY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE WAVE; SMOKING;

ADULT; AORTA; BLOOD FLOW VELOCITY; BLOOD PRESSURE; BRACHIAL ARTERY; CAROTID ARTERIES; ELASTICITY; FEMALE; FEMORAL ARTERY; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; IMMUNOASSAY; LOGISTIC MODELS; MALE; MIDDLE AGED; PULSATILE FLOW; RADIAL ARTERY;

EID: 33847112020     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2006.08.009     Document Type: Article

References (30)

1. Tan K.C., Chow W.S., Ai V.H., Bucala R., and Lam K.S. Advanced glycation end products and endothelial dysfunction in type 2 diabetes. Diabetes Care 25 (2002) 1055-1059
2. Kass D.A., Shapiro E.P., Kawaguchi M., Capriotti R., Scuteri A., deGroof R.C., and Lakatta E.G. Improved arterial compliance by a novel advanced glycation end-produce crosslink breaker. Circulation 104 (2001) 1464-1470
3. Wolffenbuttel B.H.R., Boulanger C.M., Crijns F.R.L., Huijberts M.S., Poitevin P., Swennen G.N., Vasan S., Egan J.J., Ulrich P., Cerami A., and Levy B.I. Breakers of advanced glycation end products restore large artery properties in experimental diabetes. Proc Natl Acad Sci USA 95 (1998) 4630-4634
4. Vaitkevicius P.V., Lane M., Spurgeon H., Ingram D.K., Roth G.S., Egan J.J., Vasan S., Wagle D.R., Ulrich P., Brines M., Wuerth J.P., Cerami A., and Lakatta E.G. A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys. Proc Natl Acad Sci USA 98 (2001) 1171-1175
5. Cooper M.E. Importance of advanced glycation end products in diabetes associated cardiovascular and renal disease. Am J Hypertens 17 (2004) 31S-38S
6. Kiuchi K., Nejima J., Takano T., Ohta M., and Hashimoto H. Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 85 (2001) 87-91
7. Kanauchi M., and Tsujimoto N. Advanced glycation end products in non-diabetic patients with coronary artery disease. Diabetes Care 24 (2001) 1620-1623
8. Berg T.J., Snorgaard O., Faber J., Torjesen P.A., Hildebrandt P., Mehlsen J., and Hanssen K.F. Serum levels of advanced glycation end products are associated with left ventricular diastolic function in patients with type 1 diabetes. Diabetes Care 22 (1999) 1186-1190
9. O'Rourke M., Staessen J.A., Vlachopoulos C., Duprez D., and Plante G.E. Clinical application of arterial stiffness: definitions and reference values. Am J Hypertens 15 (2002) 426-444
10. Mellinghoff A.C., Reininger A.J., Wuerth J.P., Founnds H.W., Landgraf R., and Hepp K.D. Formation of plasma advanced glycosylation end products (AGEs) has no influence on plasma viscosity. Diabetic Med 14 (1997) 832-836
11. Nagai R., Unno Y., Hayashi M.C., Masuda S., Hayase F., Kinae N., and Horiuchi S. Peroxynitrite induces formation of N(epsilon)-(carboxymethyl) lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes 51 (2002) 2833-2839
12. Horiuchi S., Araki N., and Morino Y. Immunochemical approach to characterise advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. J Biol Chem 266 (1991) 7329-7332
13. Reddy S., Bichler K.J., Wells-Knecht K.J., Thorpe S.R., and Baynes J.W. N epsilon (carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34 (1995) 10872-10878
14. Wang X., Desai K., Clausen J.T., and Wu L. Increased methylglyoxal and advanced glycation end products in kidney from spontaneously hypertensive rats. Kidney Int 66 (2004) 2315-2321
15. Schnider S.L., and Kohn R.R. Glucosylation of human collagen in ageing and diabetes mellitus. J Clin Invest 66 (1980) 1179-1181
16. Ken M.J., Light N.D., and Bailey A.J. Evidence for glucose-mediated covalent cross-linking of collagen after glycosylation in vitro. Biochem J 225 (1985) 745-752
17. Bucala R., Tracey K.J., and Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J Clin Invest 87 (1991) 432-438
18. Schmidt M.M., Vianna M., Gerlach M., Brett J., Ryan J., Kao J., Esposito C., Hegarty H., Hurley W., and Clauss M. Isolation and characterisation of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 267 (1992) 14987-14997
19. Quehenberger P., Bierhaus A., Fasching P., Muellner C., Klevesath M., Hong M., Stier G., Sattler M., Schleicher E., Speiser W., and Nawroth P.P. Endothelin 1 transcription is controlled by nuclear factor-kappa β in AGE-stimulated cultured endothelial cells. Diabetes 49 (2000) 1561-1570
20. Kislinger T., Fu C., Huber B., Qu W., Taguchi A., Du Yan S., Hofmann M., Yan S.F., Pischctsricder M., Stern D., and Schmidt A.M. N(epsilon)-(carbocymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and mutate gene expression. J Biol Chem 274 (1999) 31740-31749
21. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108 (2001) 949-955
22. Schram M.T., Schalkwijk C.G., Gootsma A.H., Fuller J.H., Chaturvedi N., and Stehouwer Coen D.A. Advanced glycation end products are associated with pulse pressure in type 1 diabetes. The EURODIAB prospective complications study. Hypertension 46 (2005) 232-237
23. Shinohara M., Thornallaey P.J., Giardino I., Beisswenger P., Thorpe S.E., Onorato J., and Brownlee M. Over-expression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation end product formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101 (1998) 1142-1147
24. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., Scioli G.A., and Fogari R. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. Hypertension 23 (2005) 1725-1729
25. Basta G., Lazzerini G., Massaro M., Simoncini T., Tanganelli P., Fu C., Kislinger T., Stern D.M., Schmidt M., and De Caterina R. Advanced glycation end products activate endothelium through signal transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105 (2002) 816-822
26. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D., Kashyap Y., Stern D.M., and Schmidt A.M. RAGE blockade stabilises established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2845
27. Taguchi A., Blood D.C., del Toro G., Canet A., Lee D.C., Qu W., Tanji N., Lu Y., Lalla E., Fu C., Hofmann M.A., Kislinger T., Ingram M., Lu A., Tanaku H., Hori O., Ogawa S., Stern D.M., and Schmidt A.M. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastasis. Nature 405 (2000) 354-360
28. Veiraiah A. Hyperglycaemia, lipoprotein glycation and vascular disease. Angiology 56 (2005) 431-438
29. Bucala R., Makita Z., Vega G., Grundy S., Koschinsky T., Cerami A., and Vlassara H. Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidaemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 91 (1994) 9441-9445
30. Onorato J.M., Thorpe S.R., and Baynes J.W. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in ageing and disease. Ann NY Acad Sci 854 (1998) 277-290